University of Chicago's ClostraBio has won support from two university funding initiatives for its food allergy medication.
ClostraBio, a US-based food allergy medication developer spun out of University of Chicago, has closed a $3.5m seed round backed by the university’s George Shultz Innovation Fund.
The round also includes funding from Chicago’s Edward Kaplin New Venture Challenge, as well as angel investors Joe Mansueto, and Daniel and Angela Oakey, a couple whose children have severe food allergies.
Founded in 2016, ClostraBio hopes to develop a drug that promotes intestinal bacteria in order to protect patients from…
